What We Do

Founded as a biology technology company, Sharp realized that it had a special set of tools to bring therapies to patients.

Sharp History

Founded as a biology technology company, Sharp applied these technologies across a wide range of therapeutic targets as we perfected the biology tools we use to discovery potential new drugs.

Working with big-Pharma customers and on internal programs we realized that we needed not only a unique set of biology tools, but also a specially designed set of test compounds to discover what we were looking for –compounds that would improve the function of mutated proteins and/or enhance the activity of the remaining un-mutated protein copy in haploinsufficiency.

That’s when we made the fateful decision, supported by our investors, to develop and use our own technologies to discover therapies where the need was greatest.

Sharp Today

Sharp has developed the CoreX™ biology, AlloChem™ chemistry and Disco™ computational technologies allowing us to discover small molecules that restore activity in mutated proteins, or that increase activity in the normal copy of the gene in the case where a only single unmutated gene remains (haploinsufficiency). The company applies these technologies across a portfolio of diseases of high unmet medical need.

A Genetic Disease Focus

We focused on genetic diseases for several reasons.

First, there remains a very high unmet need for therapies in these areas. Many genetic diseases are only treated at the level of symptoms, meaning that the disease continues to progress, and patient’s lives are not improved in the long run.

Second, unlike many diseases treated with conventional therapies, for these diseases we know the actual cause of disease, and we know when we’ve developed a treatment that reverses that cause. Therefore, we can be much more certain that patients will benefit when we do begin clinical trials.

Third, because we can identify patients through genetic testing, only patients that will benefit from therapy will be given therapy. This makes clinical trials much more likely to succeed. It also lowers costs for the healthcare system because we will not pay to treat those who will not benefit. And most importantly, it turns the diagnosis from bad news into hope.